Table 2.
Baseline demographic and clinical characteristics of the total sample and for each group
| Total (n=32) | Therapist-guided I-BA (n=11) | Self-guided I-BA (n=10) | TAU (n=11) | |
| Age, mean (SD), min–max | 15.4 (1.6), 13–17 | 14.6 (1.2), 13–17 | 15.1 (1.8), 13–17 | 16.5 (1.3), 14–17 |
| Gender, n (%) | ||||
| Female | 19 (59) | 6 (55) | 7 (70) | 6 (55) |
| Male | 13 (41) | 5 (45) | 3 (30) | 5 (45) |
| Main contact person, mothers, n (%) | 30 (94) | 9 (82) | 10 (100) | 11 (100) |
| Education of contact person | ||||
| Elementary school | 1 (3%) | 0 (0%) | 0 (0%) | 1 (3%) |
| High school | 3 (9%) | 1 (9%) | 1 (10%) | 1 (9%) |
| Higher education <2 years | 5 (16%) | 1 (9%) | 4 (40%) | 0 (0%) |
| Higher education >2 years | 21 (66%) | 7 (64%) | 5 (50%) | 9 (82%) |
| Postgraduate degree | 2 (6%) | 2 (18%) | 0 (0%) | 0 (0%) |
| Comorbidity*, n (%) | ||||
| None | 6 (19) | 1 (9) | 2 (20) | 3 (27) |
| One diagnosis | 12 (38) | 5 (45) | 3 (30) | 4 (36) |
| Two or more diagnoses | 14 (44) | 5 (45) | 5 (45) | 4 (36) |
| Anxiety disorder/s* | 23 (72) | 7 (64) | 8 (80) | 8 (73) |
| ADHD/ASD | 5 (16) | 3 (27) | 0 (0) | 2 (18) |
| Current use of antidepressants, n (%) | 2 (6) | 1 (9) | 0 (0) | 1 (3) |
| Risk of suicide† | ||||
| No suicidal ideation | 3 (9%) | 1 (9%) | 0 (0%) | 2 (18%) |
| Low risk | 16 (50%) | 6 (55%) | 4 (40%) | 6 (55%) |
| Moderate risk | 13 (41%) | 4 (36%) | 6 (60%) | 3 (27%) |
| High risk | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
*Including all anxiety disorders in MINI-KID.
†According to the definitions of suicidality used in MINI-KID.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; I-BA, internet-delivered behavioural activation; MINI-KID, Mini-International Neuropsychiatric Interview for Children; TAU, treatment as usual.